Squarepoint
LYEL icon

Squarepoint’s Lyell Immunopharma LYEL Stock Holding History

Squarepoint’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$595K Buy
42,322
+23,028
+119% +$417K ﹤0.01% 3292
2026
Q1 		$387K Buy
+19,294
New +$451K ﹤0.01% 3514
2025
Q2 		– Sell
-9,916
Closed -$107K – 4819
2025
Q1 		$107K Buy
+9,916
New +$121K ﹤0.01% 4202
2024
Q4 		– Sell
-6,775
Closed -$187K – 5314
2024
Q3 		$187K Buy
+6,775
New +$199K ﹤0.01% 3708
2024
Q2 		– Sell
-3,685
Closed -$164K – 4412
2024
Q1 		$164K Sell
3,685
-11,554
-76% -$495K ﹤0.01% 3676
2023
Q4 		$591K Buy
15,239
+12,542
+465% +$452K ﹤0.01% 2885
2023
Q3 		$79.3K Buy
+2,697
New +$128K ﹤0.01% 3591
2021
Q3 		– Sell
-2,549
Closed -$828K – 3208
2021
Q2 		$828K Buy
+2,549
New +$836K ﹤0.01% 1775

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Squarepoint's LYEL Position: Q2 2026 in Review

Squarepoint increased its Lyell Immunopharma (LYEL) stake by 119% in Q2 2026, buying an estimated $417K and bringing the position to 42,322 shares worth $595K. The position accounts for ﹤0.01% of the portfolio, ranked #3292.

Squarepoint first reported a position in LYEL in Q2 2021 and has held it in 8 quarters since. The position peaked at $828K in Q2 2021. 87 funds tracked by Wall St. Rank hold LYEL as of Q2 2026.

  • Squarepoint held 42,322 shares of Lyell Immunopharma worth $595K as of Q2 2026.
  • Squarepoint bought 23,028 Lyell Immunopharma shares in Q2 2026, an estimated $417K.
  • Lyell Immunopharma made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #3292 holding.
  • Squarepoint first reported a position in Lyell Immunopharma in Q2 2021 and has held it in 8 quarters since.
  • Squarepoint's Lyell Immunopharma position peaked at $828K in Q2 2021.
  • 87 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.